Ginkgo Results Presentation Deck

Cash runway and profitability are important in this environment, and our underwriting and structuring of the Zymergen and Bayer deals reflects that zymergen BAYER BAYER JOYN BIO Significant cost efficiencies in Zymergen transaction means recurring OpEx investment is minimal • Zymergen to progress independently planned cost and program rationalization prior to close • Post-close, Ginkgo will complete restructuring, and core Zymergen team is expected to fill significant planned hiring by Ginkgo, which is expected to accelerate growth and result in minimal additional employee costs • Upside if able to monetize Zymergen's product pipeline or restructure real estate obligations Bayer collaboration fees expected to significantly offset incremental run-rate OpEx from new ag biologicals capabilities • Some cost optimization through combination, including ability to leverage Ginkgo's platform capabilities ● Multi-year Bayer anchor contract expected to provide strong base of demand while we build base of new customers in this space, which could create significant opportunities for growth Ginkgo's -$1.4B cash balance as of 6/30/22 provides margin of safety, allowing us to lean into high ROI opportunities Transactions structured with the intention of minimizing incremental recurring operating costs Meaningful revenue opportunity from ag vertical expansion and increased efficiency and probability of success from horizontal platform improvements 20 Property of Ginkgo Bioworks Q2 2022 UPDATE & BUSINESS REVIEW

View entire presentation